UY26514A1 - "COMPOSITION FOR THE TREATMENT OF DAMAGED TISSUES". - Google Patents
"COMPOSITION FOR THE TREATMENT OF DAMAGED TISSUES".Info
- Publication number
- UY26514A1 UY26514A1 UY26514A UY26514A UY26514A1 UY 26514 A1 UY26514 A1 UY 26514A1 UY 26514 A UY26514 A UY 26514A UY 26514 A UY26514 A UY 26514A UY 26514 A1 UY26514 A1 UY 26514A1
- Authority
- UY
- Uruguay
- Prior art keywords
- composition
- damaged tissues
- treatment
- agent
- wound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
Se describe un agente farmacéutico para uso en el tratamiento (por ejemplo, curación) de tejidos danados, tal como una herida, comprendiendo el agente farmacéutico una composición que comprende: (a) un factor de crecimiento; (b) un agente inhibidor; y, opcionalmente, (c) un vehículo, diluyente o excipiente farmaceúticamente aceptable; pudiendo el agente inhibir la acción de al menos una proteína adversa específica (por ejemplo, una proteasa específica) que está regulada positivamente en un entorno de tejido danado, tal como una herida.A pharmaceutical agent for use in treating (eg, healing) damaged tissues, such as a wound, is disclosed, the pharmaceutical agent comprising a composition comprising: (a) a growth factor; (b) an inhibiting agent; and optionally (c) a pharmaceutically acceptable carrier, diluent, or excipient; the agent being able to inhibit the action of at least one specific adverse protein (eg, a specific protease) that is up-regulated in a damaged tissue environment, such as a wound.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9930768.8A GB9930768D0 (en) | 1999-12-29 | 1999-12-29 | Composition |
Publications (1)
Publication Number | Publication Date |
---|---|
UY26514A1 true UY26514A1 (en) | 2001-07-31 |
Family
ID=10867127
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY26514A UY26514A1 (en) | 1999-12-29 | 2000-12-28 | "COMPOSITION FOR THE TREATMENT OF DAMAGED TISSUES". |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP1242120A2 (en) |
JP (1) | JP2003519193A (en) |
AR (1) | AR027122A1 (en) |
AU (1) | AU1878201A (en) |
CA (1) | CA2395487A1 (en) |
CO (1) | CO5271671A1 (en) |
EC (1) | ECSP003859A (en) |
GB (1) | GB9930768D0 (en) |
GT (1) | GT200000224A (en) |
PE (1) | PE20011095A1 (en) |
UY (1) | UY26514A1 (en) |
WO (1) | WO2001049309A2 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7034132B2 (en) | 2001-06-04 | 2006-04-25 | Anderson David W | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
WO2002033085A2 (en) | 2000-10-16 | 2002-04-25 | Genentech, Inc. | Wisp polypeptides and therapeutical applications thereof |
CA2455756C (en) | 2001-07-27 | 2013-04-02 | The Board Of Regents, The University Of Texas System | Use of thrombin-derived peptides for the therapy of chronic dermal ulcers |
WO2003029819A1 (en) * | 2001-09-28 | 2003-04-10 | Takeda Chemical Industries, Ltd. | Method of screening preventive/remedy for bone/joint diseases |
JP2006514822A (en) | 2002-07-02 | 2006-05-18 | ザ ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム | Thrombin peptide derivative |
US7291596B2 (en) | 2003-12-31 | 2007-11-06 | Orthologic Corp. | Pharmaceutical composition for thrombin peptide derivatives |
CN101365715B (en) | 2005-10-07 | 2013-03-27 | P·安杰莱蒂分子生物学研究所 | Matrix metalloproteinase 11 vaccine |
RU2542471C2 (en) * | 2006-11-15 | 2015-02-20 | Коуда Терапьютикс, Инк. | Improved methods and compositions for wound healing |
KR101629504B1 (en) * | 2014-04-14 | 2016-06-10 | 주식회사 엘지생활건강 | Composition for improving skin conditions containing a combination of cytokines |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01279840A (en) * | 1988-04-28 | 1989-11-10 | Wakunaga Pharmaceut Co Ltd | Novel composition for external use |
GB9405076D0 (en) * | 1994-03-16 | 1994-04-27 | Inst Of Ophtalmology | A medical use of matrix metalloproteinase inhibitors |
-
1999
- 1999-12-29 GB GBGB9930768.8A patent/GB9930768D0/en not_active Ceased
-
2000
- 2000-12-21 CA CA002395487A patent/CA2395487A1/en not_active Abandoned
- 2000-12-21 WO PCT/IB2000/001935 patent/WO2001049309A2/en not_active Application Discontinuation
- 2000-12-21 AU AU18782/01A patent/AU1878201A/en not_active Abandoned
- 2000-12-21 CO CO00097188A patent/CO5271671A1/en not_active Application Discontinuation
- 2000-12-21 EP EP00981550A patent/EP1242120A2/en not_active Withdrawn
- 2000-12-21 JP JP2001549676A patent/JP2003519193A/en not_active Withdrawn
- 2000-12-22 GT GT200000224A patent/GT200000224A/en unknown
- 2000-12-27 AR ARP000106960A patent/AR027122A1/en not_active Application Discontinuation
- 2000-12-27 PE PE2000001405A patent/PE20011095A1/en not_active Application Discontinuation
- 2000-12-28 UY UY26514A patent/UY26514A1/en not_active Application Discontinuation
- 2000-12-28 EC EC2000003859A patent/ECSP003859A/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU1878201A (en) | 2001-07-16 |
WO2001049309A3 (en) | 2002-02-28 |
CA2395487A1 (en) | 2001-07-12 |
ECSP003859A (en) | 2002-09-27 |
EP1242120A2 (en) | 2002-09-25 |
GB9930768D0 (en) | 2000-02-16 |
WO2001049309A2 (en) | 2001-07-12 |
CO5271671A1 (en) | 2003-04-30 |
JP2003519193A (en) | 2003-06-17 |
PE20011095A1 (en) | 2001-10-27 |
AR027122A1 (en) | 2003-03-12 |
GT200000224A (en) | 2002-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0014384A (en) | Compounds for the treatment of ischemia | |
ES2176600T3 (en) | DERIVATIVE OF PROPIOFENONE AND PROCEDURES FOR PREPARATION. | |
UY26635A1 (en) | SYNERGIC METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | |
UY26724A1 (en) | METHODS AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUSES | |
BR0200782A (en) | Compounds for the treatment of ischemia | |
BR0110420A (en) | Muscarinic Agonists | |
AR020055A1 (en) | A PHARMACEUTICAL OR COSMETIC COMPOSITION CONTAINING A SUBSTANCE OF ACTIVE ENAMEL, USES OF SUCH COMPOSITION AND A METHOD TO PREPARE THE SAME. | |
ES2145913T3 (en) | METALOPROTEASE INHIBITORS. | |
ATE218581T1 (en) | CYCLOSPORINE DERIVATIVE, PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITION | |
MY130477A (en) | Pharmaceutical compositions for the treatmen of mucositis, stomatitis and behcet,s syndrome | |
HK1030880A1 (en) | Matrix protein compositions for wound healing | |
DE69116380D1 (en) | PHARMACEUTICAL PREPARATION FOR TREATING EXTENDED COAGLING TIME | |
UY26514A1 (en) | "COMPOSITION FOR THE TREATMENT OF DAMAGED TISSUES". | |
ES2124983T3 (en) | USE OF A SUBSTANCE P ANTAGONIST FOR THE TREATMENT OF RED SKIN STAINS OF NEUROGENOUS ORIGIN. | |
BR0010983A (en) | Preparations for the application of anti-inflammatory agents | |
DE69909747D1 (en) | PHARMACEUTICAL COMPOSITION, CONTAINING PEG-ASPARAGINASE, FOR THE TREATMENT OF HIV INFECTIONS | |
GEP20043231B (en) | Resorcinol Composition | |
FI932654A0 (en) | Hydroxamsyraderivat, som hindrar lipoxigenas | |
BR0014751A (en) | Compound, stereoisomer or mixture of stereoisomers, pharmaceutical composition, method of treating a patient in need of antimicrobial treatment, and use of a compound | |
AR005730A1 (en) | FORM OF FANCICLOVIR, PROCEDURE FOR PREPARING IT, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN IT AND METHOD FOR THE TREATMENT OR PROPHYLAXIS OF VIRAL INFECTIONS AND THE USE OF SUCH FORM -FANCICLOVIR MONOIDRATE. | |
ATE270110T1 (en) | MEDICINAL PRODUCT CONTAINING TISSUE INHIBITOR OF METALLOPROTEINASES-2 (TIMP-2) AS AN OSTEOANABOLIC SUBSTANCE | |
RU94044487A (en) | Use of 2-phenyl-3-aroylbenzothiophenes for male sterility treatment | |
BR0303384A (en) | Citalopram And Its Uses In The Treatment Of High Blood Pressure | |
CO5040221A1 (en) | PHUMARATE SALT OF (R) -5- (METHYLAMINOSULPHONYLMETHYL) -3- (N-METHYL-PILRROLIDIN-2-ILMETILE) -1H-INDOL, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND A PROCEDURE TO PREPARE DI-CHA SALT | |
BR0013741A (en) | Compound, process for the preparation of a compound, medication, therapeutic or prophylactic agent for fungal infectious diseases, strain, use of a compound, method for the treatment or prevention of a fungal infection, and pharmaceutical composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20120529 |